The Wall Street Journal

The obesity market is growing just fine – but investors want to know what’s next

The obesity market is growing just fine – but investors want to know what’s next
On paper, Ozempic owner Novo has an extensive pipeline, with several next-generation drugs in development.
The Wall Street Journal
By David WainerInvestors in the obesity drug market can breathe a sigh of relief – but not for long.On Wednesday, Novo Nordisk calmed fears of slowing demand, projecting a robust 20% increase in companywide sales at the midpoint of its 2025 guidance. While slightly slower than last year’s growth, that pace remains impressive in the world of pharmaceutical companies. Eli Lilly, meanwhile, on Thursday confirmed an earlier projection of about 32% revenue growth this year.After months of choppy stock performance driven by fears of a mar...

More Finance

Washington plans to open private funds to more investors
Finance

Washington plans to open private funds to more investors

 Momentum builds to change rules blocking most Americans from investing in private equity.

NZME board spill attempt - opponents near 40%
Finance

NZME board spill attempt - opponents near 40%

The bid is currently just under 11% short of the necessary numbers to succeed.

Pattrick Smellie 06 Mar 2025
Adrian Orr stands up Ben Bernanke
Finance

Adrian Orr stands up Ben Bernanke

The former Fed chair is in NZ for the central bank's marquee conference this week.

Pattrick Smellie 06 Mar 2025
Why Adrian Orr left now: a plausible theory
Finance

Pattrick Smellie: Why Adrian Orr left now: a plausible theory

Is the Government poised to free up restrictive bank capital requirements?

Pattrick Smellie 05 Mar 2025